Ping Xiao1, Jian-rong Chen2, Feng Zhou3, Chen-xi Lu4, Qichan Yang5, Guo-hua Tao3, Yi-jiang Tao6, Jing-liang Chen6. 1. Department of Respirology, Second Affiliated Hospital of Nantong University, Nantong 226001, China. Electronic address: kingfalcon@163.com. 2. Department of Respirology, Second Affiliated Hospital of Nantong University, Nantong 226001, China. Electronic address: drchenjr@163.com. 3. Biochemistry Laboratory, Second Affiliated Hospital of Nantong University, Nantong 226001, China. 4. Cardio-Thoracic Surgery, Second Affiliated Hospital of Nantong University, Nantong 226001, China. 5. Pathology Department, Second Affiliated Hospital of Nantong University, Nantong 226001, China. 6. Department of Respirology, Second Affiliated Hospital of Nantong University, Nantong 226001, China.
Abstract
BACKGROUND: Non-small cell lung cancer is the most frequently cause of cancer-related death in the world. To explore the technical feasibility, we detected aberrant promoter methylation of P16 in exhaled breath condensate which was a new, non-invasive tool for diagnosis and screening program of NSCLC. METHODS: We analyzed aberrant promoter methylation of P16 in 180 samples from 60 individuals, including 30 NSCLC patients (cancer tissues, adjacent normal lung tissues, blood plasma, and EBC), and 30 healthy controls (blood plasma and EBC) by fluorescent quantitative methylation-specific polymerase chain reaction (F-MSP). RESULTS: The positive rate of aberrant promoter methylation of P16 was 26 of 30 (86.66%) in tumor tissues, 15 of 30 (50%) in blood plasma, and 12 of 30 (40%) in EBC, we have not observed the positive methylation of P16 in the adjacent normal lung tissues, or in EBC or blood plasma from the healthy control group. CONCLUSION: We found that detected promoter methylation of P16 in EBC was feasibility, it should be an useful biomarker for diagnosis of NSCLC, it have potential prospect that detected the gene molecular in EBC because of noninvasive, specificity, convenient and repeatable. Crown
BACKGROUND:Non-small cell lung cancer is the most frequently cause of cancer-related death in the world. To explore the technical feasibility, we detected aberrant promoter methylation of P16 in exhaled breath condensate which was a new, non-invasive tool for diagnosis and screening program of NSCLC. METHODS: We analyzed aberrant promoter methylation of P16 in 180 samples from 60 individuals, including 30 NSCLCpatients (cancer tissues, adjacent normal lung tissues, blood plasma, and EBC), and 30 healthy controls (blood plasma and EBC) by fluorescent quantitative methylation-specific polymerase chain reaction (F-MSP). RESULTS: The positive rate of aberrant promoter methylation of P16 was 26 of 30 (86.66%) in tumor tissues, 15 of 30 (50%) in blood plasma, and 12 of 30 (40%) in EBC, we have not observed the positive methylation of P16 in the adjacent normal lung tissues, or in EBC or blood plasma from the healthy control group. CONCLUSION: We found that detected promoter methylation of P16 in EBC was feasibility, it should be an useful biomarker for diagnosis of NSCLC, it have potential prospect that detected the gene molecular in EBC because of noninvasive, specificity, convenient and repeatable. Crown
Authors: André Luis Giacometti Conceição; Erica Babeto; Natalia Maria Candido; Fernanda Craveiro Franco; Débora Aparecida Pires de Campos Zuccari; Jane Lopes Bonilha; José Antônio Cordeiro; Marilia Freitas Calmon; Paula Rahal Journal: J Cancer Date: 2015-05-23 Impact factor: 4.207
Authors: Aditi Mehta; Julio Cordero; Stephanie Dobersch; Addi J Romero-Olmedo; Rajkumar Savai; Johannes Bodner; Cho-Ming Chao; Ludger Fink; Ernesto Guzmán-Díaz; Indrabahadur Singh; Gergana Dobreva; Ulf R Rapp; Stefan Günther; Olga N Ilinskaya; Saverio Bellusci; Reinhard H Dammann; Thomas Braun; Werner Seeger; Stefan Gattenlöhner; Achim Tresch; Andreas Günther; Guillermo Barreto Journal: EMBO Mol Med Date: 2016-12-01 Impact factor: 12.137